Cataract is an eye condition characterized by the clouding of the lens, the eye's natural lens, which results in a progressive loss of vision. This disorder affects millions of people worldwide, being defined as the leading cause of preventable blindness on the planet. The only treatment is the removal of the lens with the implantation of an intraocular lens (BMC Ophthalmology, 2016). This is a descriptive, observational, qualitative, and quantitative study based on the application of a questionnaire to patients undergoing phacoemulsification at a private ophthalmology center in Aracaju, the Instituto de Olhos Cristiano Mendonça, by ophthalmology specialist Dr. C.Q.M. This questionnaire was developed as an adaptation of the Visual Function Index (VF-14) by Pereira et al. (2017). It was initially designed to assess the visual impairment caused by cataracts. The objective of this study was to evaluate personal satisfaction and verify the effectiveness of the implantation of the AcrySof IQ Vivity intraocular lens in patients who previously underwent cataract surgery, associating it with postoperative refractive outcomes. Most participants who underwent this surgery achieved excellent refractive results and visual acuity, along with a positive association with the VF-14 questionnaire.
Heart failure (HF) is not a single pathological diagnosis, but a clinical syndrome caused by a structural and/or functional abnormality of the heart, resulting in elevated intracardiac pressure or inadequate cardiac output at rest or during exercise. It is a common clinical condition found in various healthcare settings, with a vast socio-economic impact. In Brazil, HF is the leading cardiovascular cause of hospital morbidity. Thus, heart failure studies play a crucial role in the development of new drugs, enabling significant improvements in the efficacy, safety and tolerability of treatment, as well as the personalization of care for individual patients. Recent advances in pharmacotherapy have led to the evolution of new therapeutic agents with a decrease in hospitalization and mortality rates in HF. The 2023 update of the European Society of Cardiology (ESC) guidelines recommends (class IA) the administration of sodium-glucose transporter 2 inhibitors (SGLT2i) for patients with heart failure with preserved ejection fraction (HFpEF) and mildly reduced EF (HFpEF). This study aims to analyze the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in heart failure. In order to arrive at these topics, articles were collected from the PUBMED and SCIELO databases, and an analysis was carried out based on the material found in order to be able to explain the information relevant to the topic.